The New York Times on Tuesday examined how pharmaceutical lobbyists are active in all 50 states because "the industry knows that controlling drug costs is a subject with nearly universal popular appeal." All state legislatures have weighed legislation involving pharmaceuticals, and last year state lawmakers considered more than 600 bills that address prescription drugs. Some proposals were pro-industry, including measures to protect manufacturers from product liability claims and to expand access to brand-name drugs, but "several states have passed laws that represent a barely perceptible shift toward regulation" of drug costs, the Times reports.
Full Article
# posted by madthumbs @ 12:56 PM
